ArticleClinical and translational science2022
An association study of ABCG2 rs2231142 on the concentrations of allopurinol and its metabolites.
Article in Clinical and translational science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- A systematic review of single nucleotide polymorphisms affecting allopurinol pharmacokinetics and serum uric acid level.Pharmacogenomics · 2024Pooled it
- Longitudinal Examination of the UA/HDL-C Ratio as a Biomarker for Fatty Liver Disease: Findings from a Five-Year Follow-Up. Genetics of Atherosclerotic Disease (GEA) Study.Diagnostics (Basel, Switzerland) · 2026Article
- Association of ABCG2 gene variants with urate levels in Mexican patients with type 2 diabetes and chronic kidney disease.Scientific reports · 2026Article
- A Study Of the effect of Sex on drug dosing, concentrations, and pharmacogenomics in the Montreal Heart Institute Hospital Cohort (SOS-PGx): methodology and research progress.European journal of clinical pharmacology · 2025Article
- The genetics of gout: translation into clinical practice.Therapeutic advances in musculoskeletal disease · 2025Review
- Association of rare and common genetic variants in MOCOS with inadequate response to allopurinol.Rheumatology (Oxford, England) · 2024Article
- Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.Science (New York, N.Y.) · 2024Article
- A Genome-Wide Association Study of Oxypurinol Concentrations in Patients Treated with Allopurinol.Journal of personalized medicine · 2024Article
- Impact of amiodarone use on metoprolol concentrations, α-OH-metoprolol concentrations, metoprolol dosing and heart rate: A cross-sectional study.Pharmacology research & perspectives · 2023Article
- Population pharmacokinetics, pharmacodynamics and pharmacogenetics modelling of oxypurinol in Hmong adults with gout and/or hyperuricemia.British journal of clinical pharmacology · 2023Article
- Females present higher dose-adjusted drug concentrations of metoprolol and allopurinol/oxypurinol than males.Clinical and translational science · 2023Article
- Cannabis Pharmacogenomics: A Path to Personalized Medicine.Current issues in molecular biology · 2023Review
- The impact of genetic variability in urate transporters on oxypurinol pharmacokinetics.Clinical and translational science · 2023Article
- An association study of ABCG2 rs2231142 on the concentrations of allopurinol and its metabolites.Clinical and translational science · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
ABCG2 is a gene that codes for the human breast cancer resistance protein (BCRP). It is established that rs2231142 G>T, a single nucleotide polymorphism of the ABCG2 gene, is associated with gout and poor response to allopurinol, a uric acid-lowering agent used to treat this condition. It has also been suggested that oxypurinol, the primary active metabolite of allopurinol, is a substrate of the BCRP. We thus hypothesized that carrying the rs2231142 variant would be associated with decreased oxypurinol concentrations, which would explain the lower reduction in uric acid. We performed a cross-sectional study to investigate the association between the ABCG2 rs2231142 variant and oxypurinol, allopurinol, and allopurinol riboside concentrations in 459 participants from the Montreal Heart Institute Hospital Cohort. Age, sex, weight, use of diuretics, and estimated glomerular filtration rate were all significantly associated with oxypurinol plasma concentration. No association was found between rs2231142 and oxypurinol, allopurinol and allopurinol riboside plasma concentrations. Rs2231142 was not significantly associated with daily allopurinol dose in the overall population, but an association was observed in men, with T carriers receiving higher doses. Our results do not support a major role of ABCG2 in the pharmacokinetics of allopurinol or its metabolites. The underlying mechanism of the association between rs2231142 and allopurinol efficacy requires further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.